326 related articles for article (PubMed ID: 29643249)
21. Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses.
Chuang GY; Lai YT; Boyington JC; Cheng C; Geng H; Narpala S; Rawi R; Schmidt SD; Tsybovsky Y; Verardi R; Xu K; Yang Y; Zhang B; Chambers M; Changela A; Corrigan AR; Kong R; Olia AS; Ou L; Sarfo EK; Wang S; Wu W; Doria-Rose NA; McDermott AB; Mascola JR; Kwong PD
J Virol; 2020 Jun; 94(13):. PubMed ID: 32295908
[TBL] [Abstract][Full Text] [Related]
22. Exploration of a Sequential Gp140-Gp145 Immunization Regimen with Heterologous Envs to Induce a Protective Cross-Reactive HIV Neutralizing Antibody Response In Non-human Primates.
Ding X; Cao K; Wang J; Wan Y; Chen Q; Ren Y; Zheng Y; Zhu M; Tian R; Wang W; Zhao C; Zhang X; Xu J
Virol Sin; 2021 Aug; 36(4):784-795. PubMed ID: 33723807
[TBL] [Abstract][Full Text] [Related]
23. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
[TBL] [Abstract][Full Text] [Related]
24. HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.
Sliepen K; Sanders RW
Expert Rev Vaccines; 2016; 15(3):349-65. PubMed ID: 26654478
[TBL] [Abstract][Full Text] [Related]
25. Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1).
Killick MA; Grant ML; Cerutti NM; Capovilla A; Papathanasopoulos MA
Vaccine; 2015 Nov; 33(46):6298-306. PubMed ID: 26432912
[TBL] [Abstract][Full Text] [Related]
26. Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms.
Murji AA; Qin JS; Hermanus T; Morris L; Georgiev IS
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372503
[TBL] [Abstract][Full Text] [Related]
27. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
Hessell AJ; Malherbe DC; Pissani F; McBurney S; Krebs SJ; Gomes M; Pandey S; Sutton WF; Burwitz BJ; Gray M; Robins H; Park BS; Sacha JB; LaBranche CC; Fuller DH; Montefiori DC; Stamatatos L; Sather DN; Haigwood NL
J Immunol; 2016 Apr; 196(7):3064-78. PubMed ID: 26944928
[TBL] [Abstract][Full Text] [Related]
28. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
Stephenson KE; Wegmann F; Tomaka F; Walsh SR; Tan CS; Lavreys L; Ansel JL; Kanjilal DG; Jaegle K; Nkolola JP; Peter L; Fogel R; Bradshaw C; Tyler A; Makoni T; Howe L; Quijada D; Chandrashekar A; Bondzie EA; Borducchi EN; Yanosick KE; Hendriks J; Nijs S; Truyers C; Tolboom J; Zahn RC; Seaman MS; Alter G; Stieh DJ; Pau MG; Schuitemaker H; Barouch DH
Lancet HIV; 2020 Jun; 7(6):e410-e421. PubMed ID: 32078815
[TBL] [Abstract][Full Text] [Related]
29. Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaques.
Bowles EJ; Schiffner T; Rosario M; Needham GA; Ramaswamy M; McGouran J; Kessler B; LaBranche C; McMichael AJ; Montefiori D; Sattentau QJ; Hanke T; Stewart-Jones GB
PLoS One; 2014; 9(12):e114709. PubMed ID: 25490553
[TBL] [Abstract][Full Text] [Related]
30. Development of LIBRA-seq for the guinea pig model system as a tool for the evaluation of antibody responses to multivalent HIV-1 vaccines.
Vukovich MJ; Raju N; Kgagudi P; Manamela NP; Abu-Shmais AA; Gripenstraw KR; Wasdin PT; Shen X; Dwyer B; Akoad J; Lynch RM; Montefiori DC; Richardson SI; Moore PL; Georgiev IS
J Virol; 2024 Jan; 98(1):e0147823. PubMed ID: 38085509
[TBL] [Abstract][Full Text] [Related]
31. An Enhanced Synthetic Multiclade DNA Prime Induces Improved Cross-Clade-Reactive Functional Antibodies when Combined with an Adjuvanted Protein Boost in Nonhuman Primates.
Wise MC; Hutnick NA; Pollara J; Myles DJ; Williams C; Yan J; LaBranche CC; Khan AS; Sardesai NY; Montefiori D; Barnett SW; Zolla-Pazner S; Ferrari G; Weiner DB
J Virol; 2015 Sep; 89(18):9154-66. PubMed ID: 26085155
[TBL] [Abstract][Full Text] [Related]
32. Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting.
Cheng C; Xu K; Kong R; Chuang GY; Corrigan AR; Geng H; Hill KR; Jafari AJ; O'Dell S; Ou L; Rawi R; Rowshan AP; Sarfo EK; Sastry M; Saunders KO; Schmidt SD; Wang S; Wu W; Zhang B; Doria-Rose NA; Haynes BF; Scorpio DG; Shapiro L; Mascola JR; Kwong PD
PLoS One; 2019; 14(4):e0215163. PubMed ID: 30995238
[TBL] [Abstract][Full Text] [Related]
33. Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop.
Ching L; Stamatatos L
J Virol; 2010 Oct; 84(19):9932-46. PubMed ID: 20660181
[TBL] [Abstract][Full Text] [Related]
34. Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer.
Nkolola JP; Bricault CA; Cheung A; Shields J; Perry J; Kovacs JM; Giorgi E; van Winsen M; Apetri A; Brinkman-van der Linden EC; Chen B; Korber B; Seaman MS; Barouch DH
J Virol; 2014 Sep; 88(17):9538-52. PubMed ID: 24965452
[TBL] [Abstract][Full Text] [Related]
35. Antibody responses to prime-boost vaccination with an HIV-1 gp145 envelope protein and chimpanzee adenovirus vectors expressing HIV-1 gp140.
Emmer KL; Wieczorek L; Tuyishime S; Molnar S; Polonis VR; Ertl HC
AIDS; 2016 Oct; 30(16):2405-2414. PubMed ID: 27525550
[TBL] [Abstract][Full Text] [Related]
36. Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.
Malherbe DC; Pissani F; Sather DN; Guo B; Pandey S; Sutton WF; Stuart AB; Robins H; Park B; Krebs SJ; Schuman JT; Kalams S; Hessell AJ; Haigwood NL
J Virol; 2014 Nov; 88(22):12949-67. PubMed ID: 25210191
[TBL] [Abstract][Full Text] [Related]
37. Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein.
Dey AK; Burke B; Sun Y; Sirokman K; Nandi A; Hartog K; Lian Y; Geonnotti AR; Montefiori D; Franti M; Martin G; Carfi A; Kessler P; Martin L; Srivastava IK; Barnett SW
PLoS One; 2012; 7(1):e30233. PubMed ID: 22291921
[TBL] [Abstract][Full Text] [Related]
38. Immunization with Clinical HIV-1 Env Proteins Induces Broad Antibody Dependent Cellular Cytotoxicity-Mediating Antibodies in a Rabbit Vaccination Model.
Karlsson I; Borggren M; Jensen SS; Heyndrickx L; Stewart-Jones G; Scarlatti G; Fomsgaard A
AIDS Res Hum Retroviruses; 2018 Feb; 34(2):206-217. PubMed ID: 28982260
[TBL] [Abstract][Full Text] [Related]
39. HIV-1 Env DNA vaccine plus protein boost delivered by EP expands B- and T-cell responses and neutralizing phenotype in vivo.
Muthumani K; Wise MC; Broderick KE; Hutnick N; Goodman J; Flingai S; Yan J; Bian CB; Mendoza J; Tingey C; Wilson C; Wojtak K; Sardesai NY; Weiner DB
PLoS One; 2013; 8(12):e84234. PubMed ID: 24391921
[TBL] [Abstract][Full Text] [Related]
40. Diverse Murine Vaccinations Reveal Distinct Antibody Classes to Target Fusion Peptide and Variation in Peptide Length to Improve HIV Neutralization.
Sastry M; Changela A; Gorman J; Xu K; Chuang GY; Shen CH; Cheng C; Geng H; O'Dell S; Ou L; Rawi R; Reveiz M; Stewart-Jones GBE; Wang S; Zhang B; Zhou T; Biju A; Chambers M; Chen X; Corrigan AR; Lin BC; Louder MK; McKee K; Nazzari AF; Olia AS; Parchment DK; Sarfo EK; Stephens T; Stuckey J; Tsybovsky Y; Verardi R; Wang Y; Zheng CY; Chen Y; Doria-Rose NA; McDermott AB; Mascola JR; Kwong PD
J Virol; 2023 May; 97(5):e0160422. PubMed ID: 37098956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
